EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access

Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial

Robert J Motzer iD, Axel Bex iD, Paul Russo, Yoshihiko Tomita, Hernan Javier Cutuli, Carlos Rojas, Marine Gross-Goupil iD, Giovanni Schinzari, Bohuslav Melichar, Philippe Barthélémy, Abraham Ruiz Garcia iD, Jeffrey Sosman und 12 weitere

Journal of Clinical Oncology · 2025

DOI: 10.1200/jco.24.00773 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Robert J Motzer und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Ipilimumab, Kidney Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE CheckMate 914 is a two-part, randomized phase III trial evaluating adjuvant nivolumab plus ipilimumab (part A) or adjuvant nivolumab monotherapy (part B) versus placebo in mutually exclusive populations of patients with localized renal cell carcinoma (RCC) at high risk of postnephrectomy recurrence. Part A showed no disease-free survival (DFS) benefit for adjuvant nivolumab plus ipilimumab versus placebo. We report results from part B. METHODS Patients were randomly assigned (2:1:1) to nivolumab (240 mg once every 2 weeks for up to 12 doses), placebo, or nivolumab (240 mg once every 2 weeks for up to 12 doses) plus ipilimumab (1 mg/kg once every 6 weeks for up to four doses). The planned treatment duration was 24 weeks (approximately 5.5 months). The primary end point was DFS per blinded independent central review (BICR) for nivolumab versus placebo; safety was a secondary end point. RESULTS Overall, 825 patients were randomly assigned to nivolumab (n = 411), placebo (n = 208), or nivolumab plus ipilimumab (n = 206). With a median follow-up of 27.0 months (range, 18.0-42.4), the primary end point of improved DFS per BICR with nivolumab versus placebo was not met (hazard ratio [HR], 0.87 [95% CI, 0.62 to 1.21]; P = .40); the median DFS was not reached in either arm, and 18-month DFS rates were 78.4% versus 75.4%. The HR for DFS per investigator was 0.80 (95% CI, 0.58 to 1.12; P = .19). Grade 3-4 all-cause adverse events (AEs) occurred in 17.2%, 15.0%, and 28.9% of patients with nivolumab, placebo, and nivolumab plus ipilimumab, respectively. Any-grade treatment-related AEs led to discontinuation in 9.6%, 1.0%, and 28.4%, respectively. CONCLUSION Part B of CheckMate 914 did not meet the primary end point of improved DFS for nivolumab versus placebo in patients with localized RCC at high risk of postnephrectomy recurrence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellIpilimumabKidney NeoplasmsNeoplasm Recurrence, LocalNephrectomyNivolumabAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantDisease-Free SurvivalDouble-Blind Method

Substanzen

IpilimumabNivolumab

Autor:innen und Institutionen

  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • University College London, London, United Kingdom.
  • Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
  • Hospital Sirio Libanés, Buenos Aires, Argentina.

ORCID-Profile: Robert J Motzer, Axel Bex, Marine Gross-Goupil, Abraham Ruiz Garcia, Marc-Oliver Grimm, Jeffrey C Goh, Christian K Kollmannsberger, Suresh G Nair, Brian M Shuch, Viktor Grünwald

Förderung

  • NCI NIH HHS

Zitieren

APA

Motzer, R. J., Bex, A., Russo, P., Tomita, Y., Cutuli, H. J., Rojas, C., Gross-Goupil, M., Schinzari, G., Melichar, B., Barthélémy, P., Ruiz Garcia, A., Sosman, J., Grimm, M. O., Goh, J. C., Suarez, C., Kollmannsberger, C. K., Nair, S. G., Shuch, B. M., Huang, J., …, & Grünwald, V. (2025). Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.24.00773

Vancouver

Motzer RJ, Bex A, Russo P, Tomita Y, Cutuli HJ, Rojas C, et al. Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial. Journal of Clinical Oncology. 2025. doi:10.1200/jco.24.00773

BibTeX
@article{Motzer2025,
  author = {Motzer, Robert J and Bex, Axel and Russo, Paul and Tomita, Yoshihiko and Cutuli, Hernan Javier and Rojas, Carlos and Gross-Goupil, Marine and Schinzari, Giovanni and Melichar, Bohuslav and Barthélémy, Philippe and Ruiz Garcia, Abraham and Sosman, Jeffrey and Grimm, Marc-Oliver and Goh, Jeffrey C and Suarez, Cristina and Kollmannsberger, Christian K and Nair, Suresh G and Shuch, Brian M and Huang, Jian and Simsek, Burcin and Spiridigliozzi, Julia and Lee, Chung-Wei and van Kooten Losio, Maximiliano and Grünwald, Viktor},
  title = {Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1200/jco.24.00773}
}
Kostenlos starten →